New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy

Agostino Guida; Francesco Perri; Franco Ionna; Paolo A Ascierto; Antonio M Grimaldi

doi:10.1002/ccr3.3418

New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy

Clin Case Rep. 2020 Dec 2;9(1):61-66. doi: 10.1002/ccr3.3418. eCollection 2021 Jan.

Authors

Agostino Guida¹, Francesco Perri², Franco Ionna¹, Paolo A Ascierto³, Antonio M Grimaldi³

Affiliations

¹ Maxillo-facial and ENT Surgery Unit INT - IRCCS "Fondazione G. Pascale" Naples Italy.
² Head & Neck/Thyroid Medical Oncology Unit INT - IRCCS "Fondazione G. Pascale" Naples Italy.
³ Melanoma, Oncological Immunotherapy and Innovative Therapies Department INT - IRCCS "Fondazione G. Pascale" Naples Italy.

Abstract

Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonecrosis of the jaw. Multidisciplinary team management of these patients should be provided.

Keywords: bisphosphonate‐associated osteonecrosis; ipilimumab; medically compromised patients; medication‐related osteonecrosis of the jaw; target therapy.

Publication types

Case Reports